Sign In
Buy GSK
$50.67
-1.48 (-2.84%)
At Close: Jun 18, 2026
GSK trial shows promising results for treatment of persistent itch in rare liver disease
02:54am, Tuesday, 19'th Nov 2024
GSK PLC (LSE:GSK, NYSE:GSK)has reported positive results from its phase III trial of linerixibat, a drug being tested to treat relentless itching caused by primary biliary cholangitis (PBC). PBC is a
GSK drug meets main goal in late-stage study to treat relentless itch
02:19am, Tuesday, 19'th Nov 2024
British drugmaker GSK said on Tuesday its experimental therapy, linerixibat, met its main goal in a late-stage trial to treat patients with a so-called relentless itch associated with a rare autoimmun
Medicus Pharma unveils ex-GSK and Pfizer senior as chief medical officer
12:03pm, Monday, 18'th Nov 2024
Medicus Pharma (TSX-V:MDCX, NASDAQ:MDCX) Ltd has announced the appointment of Faisal Mehmud, formerly of GSK PLC (LSE:GSK, NYSE:GSK) and Pfizer Inc (NYSE:PFE, ETR:PFE), as chief medical officer. Mehmu
As Drug Maker Stocks Fall, Pressure Builds On PhRMA To Derail RFK, Jr.
10:03pm, Friday, 15'th Nov 2024
Stocks of major drug makers and biotech companies tumbled in trading late this week after President-elect Donald Trump announced that he wants vaccine skeptic Robert F. Kennedy Jr. to lead the U.S. De
GSK plc (GSK) Guggenheim's Inaugural Healthcare Innovation Conference (Transcript)
11:43am, Friday, 15'th Nov 2024
GSK plc (NYSE:GSK ) Guggenheim's Inaugural Healthcare Innovation Conference November 12, 2024 2:00 PM ET Company Participants Emma Walmsley - Chief Executive Officer Conference Call Participants Seamu
European And US Vaccine Stocks Are Under Pressure - Here's WHy
11:21am, Friday, 15'th Nov 2024
Some large European and U.S. vaccine maker stocks have fallen in reaction to Robert F. Kennedy Jr.'s nomination to lead the Department of Health and Human Services.
GSK at two-year low, drug firms hit on vaccine sceptic US health appointment
05:38am, Friday, 15'th Nov 2024
GSK PLC (LSE:GSK, NYSE:GSK) shares fell to a two-year low as AstraZeneca PLC also came under pressure on Friday after Robert F Kennedy Junior was announced as US health secretary. President-elect D
GSK going nowhere while key vaccines struggle, says US bank
08:44am, Tuesday, 12'th Nov 2024
GSK PLC (LSE:GSK, NYSE:GSK) looks undervalued, but the problem is that there is nothing on the horizon to change that perception according to analysts at US bank Jefferies. Downgrading its investment
CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2024 and Provides Business Update
07:20am, Tuesday, 12'th Nov 2024
Strengthened Cash, Strategic Refocus and Pipeline Progress Define Transformative Quarter €400 million upfront payment from restructured GSK collaboration reflected in financials, cash position incre
GSK price target lowered to 1,450 GBp from 1,550 GBp at Barclays
02:33pm, Friday, 08'th Nov 2024
Barclays lowered the firm's price target on GSK to 1,450 GBp from 1,550 GBp and keeps an Equal Weight rating on the shares.
Canada approves GSK's RSV vaccine for adults aged 50 to 59
09:51am, Tuesday, 05'th Nov 2024
GSK has received Canadian approval for its respiratory syncytial virus vaccine in adults between 50 and 59, the company said on Tuesday, making it the country's first authorized RSV shot for that age
GSK Q3 Earnings Top, Stock Down on Lowered '24 View for Vaccine Sales
03:06pm, Wednesday, 30'th Oct 2024
GSK's Q3 earnings beat estimates but sales miss the same. The company also lowers its outlook for vaccine sales for the rest of the year due to weak U.S. demand.
GSK plc (GSK) Q3 2024 Earnings Call Transcript
01:18pm, Wednesday, 30'th Oct 2024
GSK plc (NYSE:GSK ) Q3 2024 Earnings Conference Call October 30, 2024 8:00 AM ET Company Participants Emma Walmsley - CEO Luke Miels - Chief Commercial Officer Deborah Waterhouse - CEO, ViiV Healthcar
GSK (GSK) Q3 Earnings Surpass Estimates
10:05am, Wednesday, 30'th Oct 2024
GSK (GSK) came out with quarterly earnings of $1.27 per share, beating the Zacks Consensus Estimate of $1.16 per share. This compares to earnings of $1.26 per share a year ago.
GSK: Earnings Confirm It's On Track To Meet Guidance
09:19am, Wednesday, 30'th Oct 2024
GSK is on track to achieve its guidance for 2024, with its Q3 2024 and 9m 2024 results today. For 9m 2024, the company's turnover growth at 9% is at the upper end of the guidance range and core EPS gr
